These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30297249)

  • 1. Papulopustules and paronychia in a lung carcinoma.
    Thakur V; Daroach M; Kumaran MS
    Eur J Intern Med; 2019 Apr; 62():e5-e6. PubMed ID: 30297249
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Masago K; Irie K; Fujita S; Imamichi F; Okada Y; Katakami N; Fukushima S; Yatabe Y
    Oncology; 2018; 95(4):251-256. PubMed ID: 29902802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
    Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
    Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
    Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC
    J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
    Hotta K; Kiura K; Takigawa N; Matsuo K; Tabata M; Fujiwara Y; Tanimoto M
    J Clin Oncol; 2008 Dec; 26(35):5826-7; author reply 5827. PubMed ID: 19001344
    [No Abstract]   [Full Text] [Related]  

  • 7. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study.
    Lu CW; Wang TY; Yen CF; Chen KH; Wu CE; Wang CL; Hsu PC; Fang YF; Li SH; Ko HW; Tseng LC; Shih FY; Lin YJ; Chen MJ; Chen CB; Su Pang JH; Chung WH; Ko YS
    Int J Dermatol; 2021 Feb; 60(2):179-184. PubMed ID: 32975313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
    Lau SCM; Batra U; Mok TSK; Loong HH
    Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.
    Lee JS; Woo J; Kim TM; Kim N; Keam B; Jo SJ
    Acta Derm Venereol; 2024 Aug; 104():adv40555. PubMed ID: 39192813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
    Damyanov D; Koynov K; Naseva E; Bichev S
    J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib for non-small-cell lung cancer treatment.
    D'Incecco A; Cappuzzo F
    Expert Opin Drug Saf; 2011 Nov; 10(6):987-96. PubMed ID: 21905963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.
    Aw DC; Tan EH; Chin TM; Lim HL; Lee HY; Soo RA
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):23-31. PubMed ID: 28464435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Side effects of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)].
    Takeda K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():245-9. PubMed ID: 25831761
    [No Abstract]   [Full Text] [Related]  

  • 15. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
    Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan.
    Liu HL; Chuang CH; Chen CL; Wei PJ; Yang CJ
    J Oncol Pharm Pract; 2023 Sep; 29(6):1374-1380. PubMed ID: 36112905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.